Beutel, Goodman & Co’s Novo Nordisk NVO Stock Holding History

Beutel, Goodman & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66M	Sell	55,413 -2,300	-4%	-$98.8K	0.02%	90
2026 Q1	$2.12M	Sell	57,713 -2,300	-4%	-$109K	0.01%	98
2025 Q4	$3.05M	Sell	60,013 -3,425	-5%	-$175K	0.02%	84
2025 Q3	$3.52M	Sell	63,438 -9,080	-13%	-$531K	0.02%	81
2025 Q2	$5M	Sell	72,518 -6,645	-8%	-$452K	0.03%	77
2025 Q1	$5.5M	Buy	+79,163	New	+$6.54M	0.03%	78

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Beutel, Goodman & Co's NVO Position: Q2 2026 in Review

Beutel, Goodman & Co reduced its Novo Nordisk (NVO) stake by 4% in Q2 2026, selling an estimated $98.8K and leaving 55,413 shares worth $2.66M. The position accounts for 0.02% of the portfolio, ranked #90.

Beutel, Goodman & Co first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.5M in Q1 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Beutel, Goodman & Co held 55,413 shares of Novo Nordisk worth $2.66M as of Q2 2026.
Beutel, Goodman & Co sold 2,300 Novo Nordisk shares in Q2 2026, an estimated $98.8K.
Novo Nordisk made up 0.02% of Beutel, Goodman & Co's portfolio in Q2 2026, its #90 holding.
Beutel, Goodman & Co first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
Beutel, Goodman & Co's Novo Nordisk position peaked at $5.5M in Q1 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Beutel, Goodman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.